Compare HII & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | ROIV |
|---|---|---|
| Founded | 1886 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | HII | ROIV |
|---|---|---|
| Price | $316.02 | $21.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $320.60 | $21.19 |
| AVG Volume (30 Days) | 407.4K | ★ 7.1M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.50 | N/A |
| Revenue | ★ $12,012,000,000.00 | $20,329,000.00 |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $5.24 | $376.94 |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $158.88 | $8.73 |
| 52 Week High | $330.00 | $21.35 |
| Indicator | HII | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 65.67 |
| Support Level | $304.01 | $19.96 |
| Resistance Level | $317.78 | $20.99 |
| Average True Range (ATR) | 8.31 | 0.62 |
| MACD | -0.84 | -0.13 |
| Stochastic Oscillator | 83.19 | 88.32 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.